The future of GLP-1, or more specifically, semaglutide for alcohol craving management, looks promising, with ongoing research and clinical trials expanding our understanding of its potential
For now, they remain an area of scientific interestnot clinical therapy
The vial-and-syringe approach used with compounded GLP-1 medications requires more steps and user knowledge
Who should not take GLP-1 medications
Our unique volumizing complex plus patent-pending XOSM Technology improves visible deflation, sagging, crepey skin texture, dehydration and wrinkles for a visibly radiant, younger-looking complexion
The drug shows promise with "statistically significant and dose-proportional weight loss" observed across cohorts and a notable average of 8.4% weight loss in the highest dose cohort at four weeks